Pharma & Biotech Mergers & Acquisitions News
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Takeda Pharmaceutical has confirmed it is discussing with the European Union the possibility of offloading Shire’s SHP647 and certain associated rights, as a way of avoiding overlap with its gastroenterology portfolio. 29 October 2018
Pharmaceutical
Nine months after announcing that it would stop R&D into new neuroscience drugs, including its work in Alzheimer’s and Parkinson’s diseases, the world’s largest drug company has shown that it is not entirely giving up on this space. 23 October 2018
Pharmaceutical
Among news on clinical trials reporting last week, Bristol-Myers Squibb’s Opdivo failed to meet its endpoint in a Phase III study for small cell lung cancer, while, after a timeout of the limelight, Roche’s Kadcyla proved its worth in breast cancer. On government affairs, US proposals for drugmakers to show prices in direct-to-consumer (DTC) adverts attracted attention. Also of note, Pfizer gained US Food and Drug Administration approval for its new breast cancer drug Talzenna, and Novartis announced it has reached agreement to acquire oncology drug developer Endocyte. 21 October 2018
Biotechnology
Japan’s Sosei has announced that it will not take up an option to acquire more equity in MiNA Therapeutics, the British RNA activation therapeutics company. 18 October 2018
Pharmaceutical
Swiss pharma giant Novartis today announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. 18 October 2018
Biotechnology
After already penning two licensing deals in the past few months, HiFiBiO Therapeutics has today announced the acquisition of H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development of novel immuno-oncology therapeutics. 16 October 2018
Pharmaceutical
USA-based companies Alliqua BioMedical and Adynxx, have announced that they have entered into a definitive merger agreement. 12 October 2018
Biosimilars
The Mundipharma global network of independent associated companies has today added development capabilities to its biosimilars platform with the purchase of biosimilars development company Cinfa Biotech, which was created in 2013 as part of the Spanish Infarco Group. 10 October 2018
Biotechnology
Swiss rare diseases focused biotech Therachon today announced the acquisition of Canada-based GLyPharma Therapeutic for an undisclosed amount. 9 October 2018
Biotechnology
Sitryx, a new, Oxford, UK-based biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces it has closed its Series A financing round. 8 October 2018
Pharmaceutical
A few of pharma's big companies, including Boehringer Ingelheim, Allergan and Roche were involved in acquisitions in September. 1 October 2018
Biotechnology
Swiss pharma giant Roche has made a third bolt-on acquisition this year, today taking control of Tusk Therapeutics. 28 September 2018
Biotechnology
It’s not often that the company announcing an acquisition sees a significant share price spurt, but this was certainly the case on Wednesday for Alexion Pharmaceuticals, which gained over 5.1% to $135.61. 27 September 2018
Pharmaceutical
Following a ‘letter of intent’ back in June, Florida, USA-based Nutriband (OTCQB: NTRB) has now announced the signing of the definitive acquisition agreement to acquire Carmel Biosciences. 27 September 2018
Biotechnology
In the context of a competitive, some say overheated, market for mergers and acquisitions, Johnson & Johnson’s $30 billion purchase of Swiss biotech Actelion could be seen as a value-destructive move for shareholders. 26 September 2018
Biotechnology
US biotech firm Cerecor has agreed to acquire Ichorion Therapeutics, a privately-held biopharmaceutical company focused on developing treatments and increasing awareness of inherited metabolic disorders known as Inborn Errors of Metabolism (IEMs). 26 September 2018
Pharmaceutical
Privately-held US firm Tris Pharma today announced the acquisition of NextWave Pharmaceuticals, a wholly-owned subsidiary of Pfizer, including two key attention deficit hyperactivity disorder (ADHD) treatments. 25 September 2018
Pharmaceutical
Among last week’s regulatory events, new of US Food and Drug Administration approval of Teva Pharmaceutical Industries’ migraine prophylaxis drug Ajovy (fremanezumab) is seen as a turning point for the Israeli company. There was also FDA approval for AstraZeneca’s leukemia drug Lumoxiti, and the agency lifted the partial clinical hold on Mersana’s XMT-1522 cancer drug, but the company’s shares fell. Allergan’s acquisition of medical aesthetics firm Bonti is seen as good news for the firm. On the research front, Viking Therapeutics soared on strong clinical data for its liver disease drug VK2809, but it may not be the first to come to the market. 23 September 2018
Pharmaceutical
New Jersey, USA-based rare diseases drugmaker Amicus Therapeutics has dived into the gene therapy sector. 21 September 2018
Pharmaceutical
Following a public comment period, the US Federal Trade Commission has approved a final order that settles charges that Catalan pharma-chemical company Grifols’ $286 million acquisition of USA-based Biotest Pharmaceuticals is anticompetitive and violates federal antitrust law. 19 September 2018
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co 23 October 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure’s key product Optune Lua for lung cancer patients. Also, German biotech BioNTech and its US partner OncoC4 received a partial clinical hold from the FDA on the Phase III trial of gotistobart in lung cancer. The European Medicines Agency’s human health committee, CHMP, Reaffirmed its non-approval of PTC Therapeutic’s Translarna. 20 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Biotechnology
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze